A Study of Pembrolizumab (MK-3475) in Pediatric Participants With Advanced Melanoma or Advanced, Relapsed, or Refractory PD-L1-Positive Solid Tumors or Lymphoma (KEYNOTE-051)
Pembrolizumab (MK-3475) is approved for the treatment of advanced cancer in adults. This phase I/II trial investigates the safety and antitumour activity of pembrolizumab for pediatric patients with either advanced melanoma, a PD-L! positive advanced, relapsed or refractory solid tumor or other lymphoma. Pembrolizumab is administered intravenous.
Merck Sharp Dohme Corp.